What is AOD-9604?
AOD-9604 is a modified fragment derived from the C-terminal region of human growth hormone. It was developed to explore whether some metabolic effects of growth hormone could be separated from its growth-promoting actions.
Proposed mechanism
The proposed biology centers on lipid metabolism rather than direct growth-hormone receptor activation. Early development aimed to influence fat breakdown while minimizing broader endocrine effects, but a definitive therapeutic mechanism in humans was never established.
What has been published?
AOD-9604 entered clinical development for obesity and was reviewed in the investigational-drug literature. The program generated human exposure data but did not lead to an approved obesity treatment.
Current human evidence
Human trials did not establish a sufficiently convincing clinical benefit to produce an approved weight-management medicine. This makes AOD-9604 a useful example of why biological plausibility does not guarantee useful clinical efficacy.
Regulatory status
AOD-9604 remains investigational and is not an FDA-approved obesity drug.
Possible areas of research interest
- Fat-metabolism research
- Growth-hormone fragment design
- Obesity-drug development
- Translational pharmacology
Important limitations
- Development did not establish an approved indication
- Consumer claims often exceed trial outcomes
- Current research-market products are not equivalent to a regulated medicine
- Long-term unsupervised use is not well characterized
References
AEVLI prioritizes primary publications and regulator materials over anecdotal claims.